Imagabalin (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name PD-0332334) was an investigational drug that acts as a ligand for the α₂δ subunit of the voltage-dependent calcium channel, with some selectivity for the α₂δ₁ subunit over α₂δ₂. It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer. The drug is no longer under development.

Protein engineering has been used to modify the Vibrio fluvialis aminotransferase to catalyze the asymmetric transamination of a synthetic intermediate.